• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Projects
  • Research Data
  • Organizations
  • Researchers
  • More
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice
 

Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice

Options
  • Details
  • Files
BORIS DOI
10.7892/boris.65308
Publisher DOI
10.1186/s13023-014-0107-7
PubMed ID
25081276
Description
BackgroundHepatorenal tyrosinaemia (Tyr 1) is a rare inborn error of tyrosine metabolism. Without treatment, patients are at high risk of developing acute liver failure, renal dysfunction and in the long run hepatocellular carcinoma. The aim of our study was to collect cross-sectional data.MethodsVia questionnaires we collected retrospective data of 168 patients with Tyr 1 from 21 centres (Europe, Turkey and Israel) about diagnosis, treatment, monitoring and outcome. In a subsequent consensus workshop, we discussed data and clinical implications.ResultsEarly treatment by NTBC accompanied by diet is essential to prevent serious complications such as liver failure, hepatocellular carcinoma and renal disease. As patients may remain initially asymptomatic or develop uncharacteristic clinical symptoms in the first months of life newborn mass screening using succinylacetone (SA) as a screening parameter in dried blood is mandatory for early diagnosis. NTBC-treatment has to be combined with natural protein restriction supplemented with essential amino acids. NTBC dosage should be reduced to the minimal dose allowing metabolic control, once daily dosing may be an option in older children and adults in order to increase compliance. Metabolic control is judged by SA (below detection limit) in dried blood or urine, plasma tyrosine (<400 ¿M) and NTBC-levels in the therapeutic range (20¿40 ¿M). Side effects of NTBC are mild and often transient.Indications for liver transplantation are hepatocellular carcinoma or failure to respond to NTBC. Follow-up procedures should include liver and kidney function tests, tumor markers and imaging, ophthalmological examination, blood count, psychomotor and intelligence testing as well as therapeutic monitoring (SA, tyrosine, NTBC in blood).ConclusionBased on the data from 21 centres treating 168 patients we were able to characterize current practice and clinical experience in Tyr 1. This information could form the basis for clinical practice recommendations, however further prospective data are required to underpin some of the recommendations.
Date of Publication
2014-08-01
Publication Type
article
Subject(s)
600 - Technology::610 - Medicine & health
Language(s)
en
Contributor(s)
Mayorandan, Sebene
Meyer, Uta
Gokcay, Gülden
Segarra, Nuria
de Baulny, Hélène
van Spronsen, Francjan
Zeman, Jiri
de Laet, Corinne
Spiekerkoetter, Ute
Thimm, Eva
Maiorana, Arianna
Dionisi-Vici, Carlo
Moeslinger, Dorothea
Brunner-Krainz, Michaela
Lotz-Havla, Amelie
Cocho de Juan, José
Couce Pico, Maria
Santer, René
Scholl-Bürgi, Sabine
Mandel, Hanna
Bliksrud, Yngve
Freisinger, Peter
Aldamiz-Echevarria, Luis
Hochuli, Michel
Gautschi, Matthiasorcid-logo
Universitätsklinik für Kinderheilkunde
Endig, Jessica
Jordan, Jens
McKiernan, Patrick
Ernst, Stefanie
Morlot, Susanne
Vogel, Arndt
Sander, Johannes
Das, Anibh
Additional Credits
Universitätsklinik für Kinderheilkunde
Series
Orphanet journal of rare diseases
Publisher
BioMed Central
ISSN
1750-1172
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: 4f1f0f [ 1.12. 12:07]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo